1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
Delayed Japan Exchange  -  09:52 2022-08-16 pm EDT
2041.50 JPY   -0.07%
08/10Verizon Business selected to transform Astellas Pharma's global network infrastructure
AQ
08/10Verizon Communications Unit Wins Network Management Contract From Astellas Pharma
MT
08/09Astellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovation in Cancer Care Beyond Medicine
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Japan's Nikkei retreats from 6-week high as Astellas, Sony drag

06/01/2022 | 10:58pm EDT

TOKYO, June 2 (Reuters) - Japan's Nikkei share average retreated from a six-week high on Thursday, with tech shares leading the slide — in line with losses on Wall Street overnight amid simmering worries about global inflation.

The Nikkei fell 0.17% to 27,411.58 as of the midday break, but was off the day's lows at 27,251.24. The benchmark closed at 27,457.89 in the previous session, the highest since April 21.

Of the index's 225 component stocks, 116 fell versus 102 that rose and seven that were flat.

Tech had been the worst-performing sector most of the morning, but entered the break 1.08% lower, outpaced by a 1.48% drop for healthcare and a 1.56% tumble for energy. Utilities were the only gainers, up 1.25%.

The broader Topix sank 0.54% to 1,928.12. The growth index tumbled 0.81%, compared with a 0.3% decline for value shares.

The U.S. S&P 500 dropped 0.75% overnight and the Nasdaq slid by a similar amount, with rate-sensitive tech shares hurt as the benchmark U.S. long-term Treasury yields climbed to a two-week high of 2.95%.

"It's difficult to actively buy stocks" amid the rise in U.S. yields, said a market participant at a Japanese securities company.

"Rather than there being some specific news to trade on, selected value stocks are getting bought," said a market participant at a different domestic securities firm.

Market sentiment has remained fragile amid simmering economic uncertainty caused by aggressive Federal Reserve interest rate hikes and their potential to choke U.S. growth, along with the inflationary pressures from the protracted Russia-Ukraine war and China's draconian zero-COVID measures.

Astellas Pharma was the Nikkei's worst performer, sliding 3.95%, followed by tech company Fujitsu's 3.75% decline and a 2.99% drop for healthcare company M3.

Security software developer Trend Micro was next with a 2.94% retreat. Sony Group fell 2.79% and energy company Inpex lost 2.56%. (Reporting by Tokyo markets team; editing by Uttaresh.V)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTELLAS PHARMA INC. -0.10% 2041.5 Delayed Quote.9.60%
FUJITSU LIMITED 0.12% 16990 Delayed Quote.-13.84%
INPEX CORPORATION -0.14% 1467 Delayed Quote.48.80%
M3, INC. -0.08% 4983 Delayed Quote.-18.30%
SONY GROUP CORPORATION 2.46% 11890 Delayed Quote.-19.97%
TREND MICRO -1.53% 8960 Delayed Quote.38.34%
All news about ASTELLAS PHARMA INC.
08/10Verizon Business selected to transform Astellas Pharma's global network infrastructure
AQ
08/10Verizon Communications Unit Wins Network Management Contract From Astellas Pharma
MT
08/09Astellas Oncology Announces Grand Prize Winner in Annual C3 Prize to Cultivate Innovati..
AQ
08/02Astellas Pharma Shares Sink 3% as Weak Yen Drags Fiscal Q1 Attributable Profit Down
MT
08/02Astellas Pharma Inc. Announces Executive Changes
CI
08/01TRANSCRIPT : Astellas Pharma Inc., Q1 2023 Earnings Call, Aug 01, 2022
CI
08/01ASTELLAS PHARMA INC. : Press Release
CO
08/01ASTELLAS PHARMA INC. : 1st quarter results
CO
07/31ASTELLAS PHARMA : Financial Results (Q1/FY2022)
PU
07/31ASTELLAS PHARMA : Presentation Material for Information Meeting (Q1/FY2022)
PU
More news
Financials
Sales 2023 1 448 B 10 780 M 10 780 M
Net income 2023 211 B 1 574 M 1 574 M
Net cash 2023 366 B 2 724 M 2 724 M
P/E ratio 2023 17,4x
Yield 2023 2,94%
Capitalization 3 733 B 27 798 M 27 798 M
EV / Sales 2023 2,33x
EV / Sales 2024 2,13x
Nbr of Employees 14 522
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 2 043,00 JPY
Average target price 2 600,00 JPY
Spread / Average Target 27,3%
EPS Revisions
Managers and Directors
Kenji Yasukawa Chairman, President & Chief Executive Officer
Minoru Kikuoka Chief Financial Officer
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Mamoru Sekiyama Independent Outside Director
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.9.60%28 146
JOHNSON & JOHNSON-2.05%436 680
ELI LILLY AND COMPANY12.34%298 298
PFIZER, INC.-15.56%279 215
ROCHE HOLDING AG-16.14%277 502
ABBVIE INC.5.28%251 582